Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rAd5-EBV-LMP2
- Development stage
- Phase 1
- Lead developer
- Yabao Pharmaceutical
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Intramuscular
01
Overview
rAd5-EBV-LMP2 is a therapeutic vaccine candidate designed to treat Epstein-Barr virus (EBV)-associated cancers, particularly nasopharyngeal carcinoma (NPC). It utilizes a recombinant serotype 5 adenoviral vector (rAd5) to deliver the gene encoding EBV latent membrane protein 2 (LMP2), an antigen implicated in NPC progression. The vaccine aims to stimulate antigen-specific cellular immunity by eliciting cytotoxic T lymphocyte responses against LMP2-expressing tumor cells. In phase I clinical trials, the vaccine was administered intramuscularly and demonstrated good tolerability with mostly mild adverse events such as fatigue, myalgia, cough, and injection site tenderness. Immunologically, it increased the proportion of CD3+CD4+ T cells in peripheral blood at higher doses. The high dose regimen is recommended for further study in phase II trials[1][6][9].
- Other names
- recombinant adenovirus type 5 encoding Epstein-Barr virus latent membrane protein 2rAd5-EBV-LMP2 vaccinerAd-5-EBV-LMP2 vaccinerAd 5-EBV-LMP2 vaccine
02
Targets
PSMB9 (Immunoproteasome subunit beta type-1i)
Beyond the preview
Go deeper on rAd5-EBV-LMP2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rAd5-EBV-LMP2.